|

Rifaximin-α (Alfa Wassermann S.p.A., Italy) Clinical Trials

1 actively recruiting trial

Pipeline

Early 1: 1

Top Sponsors

  • Shanghai Changzheng Hospital1

Indications

  • Liver Disease1
  • Metabolic Dysfunction-Associated Steatotic Liver Disease1

Other1 trial

Efficacy and Safety of Rifaximin-α in Treating MASLD
Early 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.